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Decreased Probability of Initial Pain Cessation in
Classic Trigeminal Neuralgia Treated With Gamma
Knife Surgery in Case of Previous Microvascular
Decompression: A Prospective Series of 45 Patients
With .1 Year of Follow-up
BACKGROUND: Microvascular decompression (MVD) is the reference technique for
pharmacoresistant trigeminal neuralgia (TN).
OBJECTIVE: To establish whether the safety and efficacy of Gamma Knife surgery for
recurrent TN are influenced by prior MVD.
METHODS: Between July 1992 and November 2010, 54 of 737 patients (45 of 497 with
.1 year of follow-up) had a history of MVD (approximately half also with previous
ablative procedure) and were operated on with Gamma Knife surgery for TN in the
Timone University Hospital. A single 4-mm isocenter was positioned in the cisternal
portion of the trigeminal nerve at a median distance of 7.6 mm (range, 3.9-11.9 mm)
anterior to the emergence of the nerve. A median maximum dose of 85 Gy (range, 70-90
Gy) was delivered.
RESULTS: The median follow-up time was 39.5 months (range, 14.1-144.6 months).
Thirty-five patients (77.8%) were initially pain free in a median time of 14 days (range, 0-
180 days), much lower compared with our global population of classic TN (P = .01). Their
actuarial probabilities of remaining pain-free without medication at 3, 5, 7, and 10 years
were 66.5%, 59.1%, 59.1%, and 44.3%. The hypoesthesia actuarial rate at 1 year was 9.1%
and remained stable until 12 years (median, 8 months).
CONCLUSION: Patients with previous MVD showed a significantly lower probability of
initial pain cessation compared with our global population with classic TN (P = .01). The
toxicity was low (only 9.1% hypoesthesia); furthermore, no patient reported bothersome
hypoesthesia. However, the probability of maintaining pain relief without medication
was 44.3% at 10 years, similar to our global series of classic TN (P = .85).
KEY WORDS: Gamma knife surgery, Previous MVD, Recurrent trigeminal neuralgia
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T
rigeminal neuralgia (TN) is a very disabling
facial pain disorder. Several surgical meth-
ods, including balloon microcompression,
percutaneous radiofrequency, percutaneous glyc-
erol rhizotomy, microvascular decompression
(MVD), and Gamma Knife surgery (GKS), are
the possible options to discuss when pharmaco-
logical treatment fails.
Several articles address the issue of the safety and
efficacy ofMVD after$1 GKS treatments.1,2 To
the best of our knowledge, there are no studies
discussing the role of GKS as a retreatment for
recurrent TN after a previous MVD.
GKS for TN was introduced by the Swedish
neurosurgeon Lars Leksell3 and further refined
by several others.4-12 GKS is currently consid-
ered the least invasive treatment with the lowest
rate of adverse effects and a similar rate of initial
efficacy.11,13
MVD of the trigeminal nerve at the root entry
zone was initially carried out on the basis of the
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observations made by Dandy14 with a technique developed by
Gardner and Miklos and further perfected by Janetta.15 Although
frequently accepted as a first-line option, its failure rates vary
between 15% and 35%, as reported in studies with long-term
follow-up.16,17 Additionally, MVD is sometimes attempted in the
absence of a clear vascular compression and consequently without
necessarily an objective compression of the trigeminal root.18
The purpose of the present study was to establish on a long-term
follow-upwhether the results in terms of safety and efficacy in patients
treated with GKS for recurrent, classic TN (CTN) could be affected
by prior MVD treatment. The population of recurrent TN patients
with prior MVD was deemed especially relevant because MVD is
regarded as the reference technique. Moreover, although the out-
comes of MVD after previous GKS are well established,1,2,5,19-24
outcomes of GKS after previousMVD have not been reported so far.
METHODS
Type of Study
The study was designed as open, self-controlled, noncomparative, and
prospective. For all patients, a case report form was created and
prospectively completed. All patients were examined before treatment,
and a magnetic resonance imaging (MRI) was done (the latest to exclude
any secondary cases). Ethics committee (CPPRB1) permission was
obtained for this study.
Diagnostic Criteria Using the International Headache
Society Definition
All patients fulfilled the criteria of the International Headache
Society.25 The type of trigeminal pain was evaluated according to the
classification proposed by Eller et al,26 comprising idiopathic TN1 and
TN2. TN1 is described as typically sharp, shooting, and electric shock–
like pain with pain-free intervals between the attacks that is present
.50% of the time; TN2 is described as an aching, throbbing, or burning
pain that is present for .50% of the time and is constant in nature
(constant background pain being the most significant attribute). Only
patients fulfilling the criteria of the TN1 type were included.
Fifty-four patients (7.3%) from our global series of 737 patients had
undergone a previous MVD. We further analyzed 45 patients with .1
year of follow-up. All patients with a history of multiple sclerosis27 or
megadolichobasilar artery compression28 were excluded from the present
analysis (reputed to have more variable results). The mean time of GKS
after MVD was 67.7 months (range, 6-326 months).
Brief Description of GKS Technique
All patients underwent GKS. After application of the Leksell Model G
stereotactic frame (Elekta Instruments AB, Stockholm, Sweden) under
local anesthesia, all patients underwent stereotactic MRI (unless there
were formal contraindications) and computed tomography for target
definition. TheMRI sequences used to identify the trigeminal nerve were
T2-type constructive interference in steady state/fast imaging employing
steady-state acquisition (Siemens; 0.5-mm thickness) without contrast
and contrast-enhanced T1-weighted images. Bone computed tomogra-
phy routinely supplements the neuroimaging investigation to correct any
distortion errors on the MRIs.10,12
Between July 1992 and November 2010, models B, C, and 4C of the
Gamma Knife (Elekta Instruments AB) were used successively.
A single 4-mm isocenter was used for all 45 patients (100%) and was
positioned in the cisternal portion of the trigeminal nerve at a median
distance of 7.6mm (range, 3.9-11.9mm) anterior to the emergence of the
nerve. This target had been used in our center since the beginning of GKS
treatments for TN, as detailed in previous studies.10,11,29 The placement
of the target depended on the individual anatomy of the patient and on
the local neurovascular conditions. Because these patients already had
a previous MVD procedure, sometimes the trigeminal nerve turned out
to be more difficult to identify (eg, the presence of the Teflon felt and
postoperative changes; Figure 1).
FIGURE 1. Six different examples of targeting in previous microvascular decompression cases.
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Amedianmaximumdose of 85Gy (range, 70-90Gy) was delivered. The
dose had been chosen according to the multicentric trial of Kondziolka
et al30 (which also included an important number of patients from our
center), which recommended a minimal dose of 70 Gy for short- and long-
term efficacy. According to the aforementioned findings, we initially
prescribe a dose of 90 Gy at the 100% isodose. Beam channel blocking was
used, depending on the dose received by 10 mm3 of the brainstem. If this
dose was found to exceed 15 Gy, we scaled down the dose and then started
plugging to avoid irradiating a longer length of the treated nerve, which has
been previously shown to dramatically increase toxicity (the so-called
Flickinger effect).7
All patientswere operated onwithGKSby the senior neurosurgeon (J.R.).
Follow-up Monitoring
Initial follow-upwas based on clinical evaluation at regular intervals of 3
months, 6 months, and 1 year after treatment and on a yearly basis
thereafter. All patients have been thoroughly examined by the authors for
proper evaluation of safety and efficacy, including facial sensory testing,
corneal reflex, and jaw motility. For long-term update of the follow-up,
telephone interviewwas considered acceptable for patients unable to come
to the outpatient clinic because of either distance or general health-related
conditions.
The patients and referring physician were instructed to pursue the
preoperative medication for at least 1 month after GKS and then were
allowed to progressively taper the drug doses in cases of pain freedom.
Every clinical evaluationmade by ourmedical teamduring the course of
follow-up was reported prospectively in the database to have continuous
and prospective up-to-date information.
The 15 items of essential data as given byZakrzewska andThomas31 for
the articles reporting outcomes of surgical treatment of TN were
followed and are presented hereafter.
Explicit Definitions of Outcome Measures
Outcome measures included the existence of initial pain cessation,
occurrence and timing of any sensory disturbance, recurrence, and
recurrence without further surgery.
Efficacy was classified according to the Barrow Neurological
Institute (BNI) scale (class I, no trigeminal pain, no medication; class
II, occasional pain not requiring medication; class IIIa, no pain,
continued medication; class IIIb, persistent pain controlled with
medication; class IV, some pain not adequately controlled with
medication; class V, severe pain/no pain relief; grade I-IIIa, significant
pain relief; grade I-IIIb, adequate pain relief; and grade IV and V are
failures).10 A successfully treated patient needed to be pain free
without medication (BNI class 1).
The degree of hypoesthesia was reported with the use of the BNI facial
hypoesthesia scale32 (class I, no facial numbness; class II, mild facial
numbness, not bothersome; class III, facial numbness, somewhat
bothersome; class IV, facial numbness, very bothersome). Corneal reflex
was assessed for all patients. Additionally, the appearance or not of
dysesthesias, paresthesias, anesthesia dolorosa, masseter muscle weakness,
neurological complications outside the trigeminal nerve territory,
systemic complications, or death was noted.
Recurrence was defined as change from class I to a lower outcome class
during the follow-up.
The latency intervals to becoming pain free or developing a recurrence
or a sensory disturbance, the date ofmedication changes, and the date of all
surgical procedures were also carefully monitored.
Definition of Recurrence (Minor and Major)
A minor recurrence was defined as well tolerated by the patient (lower
frequency and intensity of the pain) and not requiring a new surgical
therapy.
A major recurrence was defined as requiring an additional surgical
procedure. We use the term initial efficacy when the patient was pain free
with orwithoutmedication in the first 6months after the radiosurgery and
had no recurrence in the year after the procedure.
Patient Satisfaction
Patient satisfaction was evaluated during the last follow-up. We used
a semistructured interview conducted by theGKS team during the follow-
up visits. Patients were asked if they regret undergoing radiosurgery and if
they would agree to undergo this procedure again. The answers in our
semistructured questionnaire included the following: a, no regret, I would
undergo radiosurgery again with no hesitation; b, no opinion; and c, I
regret having had radiosurgery (and would not have it again).
Details of Follow-up Period (Including Median
and Range)
The median follow-up period was 39.5 months (range, 14.1-144.6
months).
Basic Demographic Data
The median age was 56.7 years (range, 28.1-82.4 years).
Pain was slightly predominant on the left side in 26 patients (57.8%) vs
on the right side in 19 (42.2%). Only 2 patients (4.4%) had bilateral pain.
Pain was mainly distributed in the V2 dermatoma in 17 patients (37.8%),
followed by V2 and V3 territory in 12 patients (26.3%); V1, V2, and V3
in 3 patients (6.7%); and V1and V2 in 2 patients (4.4%; Table 1).
TABLE 1. Preoperative Assessment
Variable
Patients, n
(%)
Sex
Male 20 (44.4)
Female 25 (55.6)
Side of pain
Right 19 (42.2)
Left 26 (57.8)
Bilateral 2 (4.4)
Pain distribution
V2 17 (37.8)
V2 and V3 12 (26.3)
V1, V2, and V3 3 (6.7)
V1 and V2 2 (4.4)
V1 0 (0)
V3 0 (0)
V1 and V3 0 (0)
Dead 0 (0)
Preoperative magnetic resonance imaging showed
persisting vascular conflict other than
megadolichobasilar compression
21 (46.7)
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In 21 cases (46.7%), there was still a neurovascular conflict on the
preoperative stereotactic MRI scan, apart from megadolichobasilar artery
compression.
Data Regarding Previous Treatments (Including
Number and Types of Previous Procedures, Resulting
Sensory Deficits, or Constant Background Pain if
the Case)
All patients had a past history of surgery, with at least 1 previous MVD
(Table 2). Twenty-five patients (55.5%) had only 1 previous procedure,
8 patients (17.8%) had 2 previous surgeries, and 12 patients (26.7%)
had$3 previous surgeries. The preoperative surgical technique used was
MVD in 45 patients (100%), radiofrequency lesion in 16 patients
(35.6%), balloon microcompression in 7 patients (15.6%), and glycerol
rhizotomy in 1 patient (2.2%).
Data of Side Effects Related to Prior
Surgical Interventions
Twenty-three patients (51.1%) had preoperative hypoesthesia, which
was mild in 21 patients (46.7%) and severe in 2 patients (4.4%). In no
patient was preoperative anesthesia present.
Statistical Analysis
All statistical analyses were performed with R software, version 2.12.0
(R Foundation for Statistical Computing, Vienna, Austria). The survival
R package was used for survival analysis. For the evaluation of outcomes
such as pain free, hypoesthesia, and recurrence, the time to event was
estimated by use of the Kaplan-Meier method. A bivariate analysis was
then performed to identify predictive factors among the collected
variables. For qualitative variables, Kaplan-Meier curves were used to
graphically represent survival among the different groups and were
compared by use of the univariate log-rank test. For all variables, the
effects were estimated and tested by fitting univariate Cox proportional
hazards regression models. Proportionality of hazards was assessed
graphically by log cumulative hazard plots. For qualitative variables, the
x2 test was performed when valid; the Fischer exact test was performed
otherwise. For quantitative variables, the Mann-Whitney test was
performed given the number of patients. All tests were 2 sided, and
values of P ,.05 were judged to be significant.
RESULTS
Initial Pain Cessation
Thirty-five patients (77.8%) experienced initial pain cessation
in amedian time of 14 days (range, 0-180 days). The initially pain-
free (BNI classes I-IIIa) actuarial rate at 14 days and 1, 2, 3, 4, 5,
and 6months was 46.7%, 62.2%, 71.1%, 73.3%, 73.3%, 73.3%,
and 77.8%, respectively, attaining at 6 months the flat part of the
curve and remaining stable thereafter. Of note, the number of
patients at risk at 0.5, 1, 2, 3, 4, 5, and 6 months was 24, 17, 13,
12, 12, 12, and 10, respectively, and the number of events was 21,
7, 4, 1, 0, 0, and 2, respectively.
Patients with previous MVD had a significantly lower proba-
bility of initial pain cessation compared with our global population
of patients with CTN with no history of MVD (P = .01; hazard
ratio [HR], 0.64). Figure 2 shows the probability of being pain
free in patients with a previous MVD procedure compared with
those from our series of 497 patients with CTN. Bilateral pain
(P = .65), continuous pain (P = .19), atypical pain (P = .61), and
the number of previous surgeries (P = .07 for 1 previous surgery,
TABLE 2. Previous Surgical Interventions and Related Side Effectsa
Variable Patients, n (%)
No prior surgery 0 (0)
Prior surgeries, n 45 (100)
1 25 (55.5)
2 8 (17.8)
$3 12 (26.7)
Type of prior surgery
Radiofrequency lesion 16 (35.6)
Balloon microcompression 7 (15.6)
Microvascular decompression 45 (100)
Glycerol rhizotomy 1 (2.2)
Side effects from prior surgery 24 (53.3)
Facial sensibility before GKS
Normal 22 (48.9)
Slight hypoesthesia 21 (46.7)
Severe hypoesthesia 2 (4.4)
Anesthesia 0 (0)
aGKS, Gamma Knife surgery.
FIGURE 2. The actuarial probability rate of initial pain cessation in previous
microvascular decompression (MVD) cases compared with our classic trigeminal
neuralgia global series without previous MVD.
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P = .12 for 2 previous surgeries, P = .18 for $3 surgeries) were
not shown to be statistical factors.
Patients with both previous MVD and thermocoagulation had
a lower probability of pain cessation, but this was not statistically
significant (HR, 0.53; 95% confidence interval [CI], 0.25-1.11;
P = .08).
Age (P = .11), topography of pain (P = .46), and time lapse to
treatment onset (P = .65) also showed no statistically significant
correlation.
Postoperative Sensory Assessment and Details of
Other Postoperative Complications if the Case
No patient developed an early complication after GKS. Two
patients (4.4%) developed delayed facial sensory loss, which
occurred in both patients within the first year after the GKS.
Hypoesthesia actuarial rate at 1 year was 9.1% and remained stable
until 12 years with a median delay of onset of 8 months. Figure 3
shows the probability of hypoesthesia onset after GKS in patients
with previous MVD.
Postoperative hypoesthesia was also assessed regarding the BNI
facial hypoesthesia scale: mild facial numbness was found in 2
patients (4.4%); facial numbness, somewhat bothersome, 0 pa-
tients (0%); and facial numbness, very bothersome in 0 patients
(0%). Table 3 shows the postoperative assessment in terms of
hypoesthesia, recurrence, and management of recurrence.
The side of the pain in patients with post-GKS hypoesthesia was
not a statistically significant correlation (P = 1).
Bilateral pain (P = .04) and previous side effects (P = .04) were
associated with a higher incidence of sensory disturbance.
The topography of the pain (P = .7), the number of previous
surgeries (P = .3), the persistence of a preoperative neurovascular
conflict (P = .2), and sex (P = 1) showed no statistically significant
correlations.
No patient developed a trigeminal motor deficit or other cranial
nerve deficits after GKS.
Management and Results of Recurrent Pain
Twelve patients (34.3%) from the initially pain-free 35 patients
experienced a recurrence in a median time of 31.2 months (range,
3.4-89.9 months).
Additional surgical treatmentwas performed for 7 patients, with
1 further surgery in 5 patients (11.1%) and 2 additional
procedures in 2 cases (4.4%);$3 surgeries were never performed
(0%). In our department, the most frequently used was balloon
microcompression in 3 patients (6.7%), followed by radio-
frequency lesion in 3 patients (6.7%), second MVD in 1 patient
(2.2%), second GKS in 1 patient (2.2%), and cortical stimulation
and glycerol rhizotomy in 0 patients.
The actuarial probability rates of maintaining pain relief
without medication were 88.6%, 66.5%, 59.1%, and 44.3% at
1, 3, 5, and 10 years, respectively; the flat part of the curve was
reached at 10 years (Figure 4). Patients with previous MVD had
a probability of maintaining pain relief similar to that of our
global population of CTN without a previous MVD (P = .85;
HR, 1.06).33
FIGURE 3. The actuarial probability of hypoesthesia onset in patients with
previous microvascular decompression. GKS, Gamma Knife surgery.
TABLE 3. Postoperative Assessmenta
Variable Patients, n (%)
Initially pain free 35 (77.8)
Post GKS sensory dysfunction 2 (4.4)
Mild 2 (100)
Severe 0 (0)
BNI facial hypoesthesia scale (GKS related)
No facial numbness 20 (44.4)
Mild facial numbness 2 (4.4)
Facial numbness, somewhat bothersome 0 (0)
Facial numbness, very bothersome 0 (0)
Recurrence of pain 12 in 35 patients (34.3)
Median time to pain recurrence (range), mo 31.21 (range 3.4-89.9)
Additional treatments after GKS 7 (15.5)
1 5 (11.1)
2 2 (4.4)
$3 0 (0)
Balloon microcompression 3 (6.7)
Radiofrequency lesion 3 (6.7)
Microvascular decompression 1 (2.2)
GKS 1 (2.2)
Glycerol rhizotomy 0 (0)
Cortical stimulation 0 (0)
aBNI, Barrow Neurological Institute; GKS, Gamma Knife surgery.
RADIOSURGERY FOR TRIGEMINAL NEURALGIA AFTER PREVIOUS MVD
NEUROSURGERY VOLUME 77 | NUMBER 1 | JULY 2015 | 91
Copyright © Congress of Neurological Surgeons. Unauthorized reproduction of this article is prohibited
A preoperative pain distributed in the V1 dermatome was
related to a much higher probability of recurrence (P = .03; HR,
7.16; 95% CI, 1.19-42.96).
Having$3 previous surgical interventions was associated with
a higher probability of maintaining pain relief, but this was not
statistically significant (P = .10).
The persistence of a neurovascular conflict despite the previous
MVD at the moment of GKS was associated with a higher
probability of recurrence (P = .03; HR, 3.97; 95% CI, 1.06-
14.89).
The existence of postoperative GKS hypoesthesia onset was not
statistically significant (P = .15).
The Probability of Recurrence Not Requiring
Further Surgery
Among the 12 patients (34.3%) who experienced a post-GKS
recurrence, 7 needed a further surgery. The actuarial probability of
recurrence not requiring any further surgery at 1, 3, and 5 years was
94.3%, 80.3%, and 73%, respectively, and remained stable until
12 years.
Sex (P = .5), age (P = .6), post-GKS hypoesthesia onset (P = .9),
side of preoperative pain (P = .19), bilateral pain (P = .6), atypical
pain (P = .9), and continuous pain (P = .7) were not found to be
statistically significant factors.
The presence of preoperative pain within the V1 dermatome
was associated with a higher risk of recurrence with further surgery
(P = .01; HR, 23.47; 95% CI, 2.11-260.52).
The number of territories involved in the preoperative pain was
not statistically significant (P = .06, with the highest rate of
recurrence with further surgery in 3 dermatomes involved; HR,
23.47; 95% CI, 2.11-260.52).
Previous MVD Cases vs Previous MVD Plus
Another Procedure
Slightly fewer than half of our patients (approximately 45%)
had also undergone another intervention.We looked for potential
selection bias in this population. We compared mainly the
outcomes for previous MVD as unique intervention and previous
MVD plus another surgical procedure. The results were not
statistically significant and were as follows: for initial pain freedom
response, P = .65 (HR, 0.858; 95% CI, 0.43-1.67); for
hypoesthesia, P = .27 (HR, 4.74; 95% CI, 0.29-75.9); and for
maintaining pain relief, P = .28 (HR = 0.508; 95% CI, 0.14-
1.73).
Furthermore, for the groupwith only previousMVD, 7 patients
had preoperative hypoesthesia and 18 (28%) did not. For the
group with previous MVD plus another surgical procedure, 16
patients had a preoperative hypoesthesia and 4 did not (80%).This
difference is statistically significant (P , .001). However, this
point is not relevant because the patients harboring a hypoesthesia
before GKS were not analyzed in terms of facial sensory
disturbance.
DISCUSSION
To date, several studies have addressed the alleged technical
difficulties when MVD is performed after previous
GKS.1,2,5,22,24,34,35 To the best of our knowledge, there is
currently no study describing GKS after MVD or the dose-
planning difficulties regarding the GKS trigeminal nerve target-
ing after previous MVD. However, clinicians must cope with this
particular situation.
It is known that pain relief tends to occur immediately after
MVD and is delayed after GKS. This fact has to be balanced with
the postoperative recovery after both MVD (eg, a few weeks) and
GKS (eg, usually the next day) techniques. Previous studies have
shown a positive association with pain freedom for bothMVD and
GKS, including the following: absence of multiple sclerosis,4,12,21
absence of a prior surgical procedure,36-38 absence of atypical
features,10,11,36,38 and blood vessel in contact with the trigeminal
nerve on preoperative MRI.39 The rate of pain relief in our
present study was 78%, less than reported for CTN general series
(including ours)4,6,8-10,12 and less than in the opposite scenario
(MVD after prior GKS), as reported by others.1
Hypoesthesia occurrence is similar in both surgical therapies,
with GKS carrying a lower risk of the major complications of
surgery, including infection, meningitis, cerebellar edema or
hemorrhage, cerebrospinal fluid leak, and hearing loss.13,40
Recurrence rates in the long term are similar, with the risk of
recurrence continuing as long as patients are followed
up.6,8,12,13,16,17,41
FIGURE 4. The actuarial probability of maintaining pain relief in previous
microvascular decompression (MVD) cases compared with our classic trigeminal
neuralgia global series without previous MVD.
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Visualizing the nerve after a prior MVD remains the most
problematic issue for GKS. Postoperative displacement of the
Teflon, the size of the trigeminal nerve (atrophy or not) and
trigeminal cistern, the persistence or not of a neurovascular
conflict, and other similar anatomic constraints make the targeting
much more challenging than in the classic situations. In these
cases, the postoperative result depends on proper targeting; this is
a crucial issue for the clinical outcomes both in terms of safety
and efficacy.
Limitations
The results presented should be interpreted carefully and may
not be generalizable to all patients treated with GKS after previous
MVD for recurrent TN. The personalized analysis of the patients,
including duration of symptoms, number and type(s) of previous
surgical procedure(s), time lapse since the previous surgery (or in
particular between prior MVD and GKS), and typical or atypical
pain, should also be carefully evaluated. Therefore, our study has
several limitations: the different surgical techniques used during
previous MVD, the image qualities when GKS was performed
(with visualization of the treated nerve frequently being difficult
and varying from one patient to another according to previous
surgery), local anatomy (small vs large trigeminal cistern, presence
of Teflon, etc), and targeting location as a factor affecting the initial
efficacy of GKS, depending on individual anatomy. Additionally,
other potential limitations reside in the lack of a control arm or the
eventual use of a propensity score–matched control group. Some
subgroup analysis in the Discussion might also have been
underpowered because of the small number of patients and events
taken into consideration. The data set might, in this context, not
exclude the possibility that patients with 2 procedures (including,
for instance, MVD and 1 ablative) could have a worse prognosis
than those with prior MVD only.
The message of this study should not be misinterpreted. We
are not advocating that GKS should not be performed on patients
with previous MVD procedures because of an initial pain relief
rate that is lower than in CTN cases. On the contrary, it may be
that these patients harbored a particular type of disease that also
was resistant to the first MVD procedure. Therefore, in these
situations, wemust be aware of the fact that these patients may be
more difficult to manage surgically. Conversely, studies also
showed a decrease in the initial efficacy of MVD after previous
destructive procedures.19
The hypoesthesia rates in the present study were low with no
bothersome cases. Additionally, the maintenance of pain relief
rates over the long term were similar to those already published in
our CTN general population.33
We think that patients could benefit more from an initial
noninvasive procedure, leaving an open door for those who need
further procedures, includingMVDand percutaneous techniques.
This has to be tailored, of course, to the individual patient and to
the baseline assessment.
MVD remains the reference technique for the majority of the
surgeons, even in the absence of a prospective randomized
comparative trial with a statistically significant number of
patients and an adequate follow-up. No definitive answer can
be given to the question of the superiority of one technique over
the other. Furthermore, significant controversy exists concern-
ing the “ideal” surgical procedure to be applied (initially or as
a retreatment) for CTN. MVD is a complex surgical procedure
that carries low but significant risks of dreadful complications.
That there is usually immediate pain relief and that the
procedure directly tackles the supposed cause of the pain by
separating the offending vessel (if one exists) from the
trigeminal nerve are advantages of MVD. In case of recurrence,
however, few neurosurgeons are keen on the idea of going back
into a previously operated field, rendering the surgery much
more complicated. The present study shows that, in this case,
GKS may be extremely helpful with very limited complication
rates. However, the significantly lower efficacy rate compared
with GKS for CTN without prior MVD has to be kept in mind
and explained to the patient, along with the long-term results,
which are as good as and comparable to those in our CTN
global series.
Themajority of authors (among those who have at their disposal
the technical and human resources allowing them to do MVD,
GKS, or percutaneous techniques) agree that the evidence for the
long-term safety and efficacy of GKS is currently sufficient for
proposing GKS as a first therapeutic option, following the policy
“from less to more invasive.”6,10,42,43 Advantages and disadvan-
tages of each technique must be exposed to the patient according
to the data provided by modern peer-reviewed series published
over the past 20 years.
CONCLUSION
In our experience, in patients with previous MVD, early pain
cessation is lower than in our CTN series, which may be related to
amore resistant entity of TN.However, long-term results are good
and are comparable to those of our CTN global series, which
makes this approach of particular interest in this subgroup of
patients.
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COMMENTS
D espitemultiple safe and effective treatments for idiopathic trigeminalneuralgia (TN), the incidence of persistent or recurrent pain in
a significant subset of patients after intervention remains a vexing prob-
lem. The authors report their cohort of patients with TN who underwent
Gamma Knife radiosurgery after having a previous microvascular
decompression. After radiosurgery, 78% of patients experienced initial
pain relief, and 44% maintained long-term pain relief without medica-
tion. Although this is not a true case-control study, this patient group (45
patients with at least 1 year of follow-up) was retrospectively compared
with their center’s large cohort of TN Gamma Knife patients (n = 497).
Although the rate of initial pain relief was lower in this cohort than in
their global population of TN Gamma Knife patients, the long-term
outcomes are quite similar. They also found no difference in outcome
between the microvascular decompression (MVD) patients who had
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MVD only before Gamma Knife and those who had additional pro-
cedures. Furthermore, Gamma Knife radiosurgery after MVD was well
tolerated, with no increased incidence of complications.
The authors clearly state their own treatment bias, namely that less
invasive techniques such as Gamma Knife radiosurgery should now be
offered as first-line therapy. Although this article provides no evidence to
bolster this claim, at the very least, it provides evidence that when pain
persists or recurs after MVD, radiosurgery is a safe and appropriate
treatment option.
Alon Y. Mogilner
New York, New York
T he authors have presented a case series of patients who underwentGamma Knife radiosurgery for recurrent trigeminal neuralgia after
microvascular decompression (and sometimes other ablative proce-
dures as well). In general, their results are promising, with 78% of
patients becoming pain free at some point. However, like with other
studies of ablative procedures, 34% of patients here had recurrent pain
at a median time of 31 months after Gamma Knife radiosurgery. The
authors also note that their long-term outcome in this group was similar
to that of patients undergoing Gamma Knife radiosurgery as primary
treatment.
This series helps to reinforce that, for the most part, the choice of
surgical procedure for trigeminal neuralgia often should be best left up to
the patient when several options would suffice (such as Gamma Knife
radiosurgery vs microvascular decompression vs radiofrequency ablation
or pencil beam convolution). Trigeminal neuralgia continues to be
a challenging clinical entity, and the ability to provide patients with more
autonomy in treatment selection, knowing that long-term outcomes may
eventually be similar, is important.
Joshua Rosenow
Chicago, Illinois
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